Navigation Links
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
Date:5/5/2009

TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function. The substudy results were published online in Circulation on May 4, 2009(1).

Prasugrel is a "prodrug" that requires the use of cytochrome P450 (CYP) enzymes to convert the drug into the active metabolite. Approximately 30 percent of Caucasians and 60 percent of Asians have reduced function in the CYP2C19 gene, which is part of the CYP system and encodes the enzymes that are responsible for converting prasugrel into its active form(2).

In the substudy, researchers examined how variation in cytochrome P450 (CYP) genes affected the response to prasugrel. In prasugrel-treated patients with acute coronary syndromes (ACS) who underwent an artery-opening procedure known as percutaneous coronary intervention (PCI), the incidence of the combined endpoint of cardiovascular death, heart attack or stroke was 8.5 percent (N=407) in those who carried at least one variant in the CYP2C19 gene that reduced its function versus 9.8 percent (N=1048) in patients without a genetic variant (P=0.27). In addition, the rate of stent thrombosis in carriers of the reduced-function variant in the CYP2C19 gene compared with non-carriers treated with prasugrel was 0.5 percent vs. 1.0 percent, respectively (P=0.48). The results also showed that rates on non-CABG-related TIMI major or minor bleeding did not significantly differ by genetic variant among those treated with prasugrel.

"It is well documented in the medical literature that particular genetic variants in the CYP2C19 gene are associated with an increased risk of cardiovascular outcomes in patients treated with c
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the nation,s ... Polaris Medical Imaging, a leader in sales, service and ... acquisition allows BC Technical to continue to expand their ... MR and CT modalities. "We are ... Mark Alvarez , president and CEO of BC ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
(Date:8/29/2014)... Diseases largely eradicated in the ... Measles was declared eliminated in 2000, yet the CDC ... 15—the highest incidence in 20 years. In July, ... cough a problem of "epidemic proportions." ... from these preventable diseases—in part because some parents (more ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... WESTON, Fla. , June 15 DHL Global Mail ... of mail-order pharmacies. DHL SMARTMAIL PHARMA SELECT ™ incorporates best ... the pharmaceutical industry. Thanks to this expertise and Global Mail,s nationwide ... accountability and value. , , ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President ... Goldman Sachs Global Healthcare Conference on Tuesday, June 15 , at ... in Los Angeles .  The presentation will be webcast on the ... , , ...
Cached Medicine Technology:DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies 2
(Date:8/31/2014)... CA (PRWEB) August 31, 2014 Kicking ... kicking coach Matt Nelson of Matt Nelson Kicking Academy ... business, and on being a National Camp Series (NCS) ... of HustedKicking.com. , "Matt Nelson is another high quality ... many attributes to coaching. He is an outstanding ...
(Date:8/31/2014)... August 31, 2014 This September, ... California State Library, celebrates 30 years of changing ... Since its inception, California’s Library Literacy Services has ... learn to read and write. , To mark ... the state is launching a month-long awareness campaign ...
(Date:8/31/2014)... 2014 With the NCAA set to ... hosted an interview with Yale University Associate Athletic Director ... Yale’s approach to ensuring student-athlete experience that is consistent ... highlighted a number of key factors that contribute to ... critical factor in creating this culture seems simple at ...
(Date:8/31/2014)... 31 August 2014: Renal denervation seems to be more ... hypertension when it includes accessory renal arteries, according to ... Schmiedel from Germany. , Dr Schmiedel said: "More than ... is defined as blood pressure (BP) greater than 140/90 ... hypertension (rHTN) and are unable to reduce BP below ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Drinking tea ... 131 000 people presented at ESC Congress today by ... "If you have to choose between tea or coffee ... are important components of our way of life. Their ... the past with sometimes divergent results. We investigated the ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 2Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 3Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
Medicine Products: